Results 191 to 200 of about 36,696 (303)

Occurrence of Sulfonylurea-resistant Biotypes of Scripus juncoides Roxb. var. ohwianus. T. Koyama in paddy fields of Hokkaido prefecture, Japan.

, 1999
洋 古原, 一男 今野, 昌和 竹川
openalex   +2 more sources

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3126-3136, April 2026.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Kazuki Aoyama, Takashin Nakayama, Yuya Kimura, Katsuhiko Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi   +16 more
wiley   +1 more source

Retraction: Cardiovascular and mortality outcomes of DPP-4 inhibitors vs. sulfonylureas as metformin add-on therapy in patients with type 2 diabetes: A systematic review and meta-analysis. [PDF]

PLoS One
PLOS One Editors.
europepmc   +1 more source

Two for the heart: Dutch Pharmacogenetic Working Group prescribing guidance on statins and sulfonylureas to reduce cardiometabolic risk

Sean P. David
openalex   +2 more sources

Rationale and design of a parallel randomised trial of a plant‐based intensive lifestyle intervention for diabetes remission: The REmission of diabetes using a PlAnt‐based weight loss InteRvention (REPAIR) trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2627-2641, April 2026.
Abstract Aims As type 2 diabetes (T2D) continues to rise globally and remains a major driver of cardiovascular disease, its remission has emerged as a therapeutic target. Current evidence supports bariatric surgery and low‐calorie diets with meal replacements.
Brighid McKay, Dayana El Chaar, Melanie Paquette, Michael Vallis, Diana Sherifali, Paul Oh, Susan Marzolini, Kaberi Dasgupta, Gillian Booth, Mike Lean, Hertzel C. Gerstein, Jordi Salas‐Salvadó, Jacqueline L. Beaudry, Christopher P. F. Marinangeli, Russell J. de Souza, Lawrence A. Leiter, Cyril W. C. Kendall, David J. A. Jenkins, John L. Sievenpiper, Laura Chiavaroli   +19 more
wiley   +1 more source

Subtype-Specific Causal Effects of Antidiabetic Drug Targets on Ovarian Cancer: Mendelian Randomization and Colocalization Evidence. [PDF]

Int J Womens Health
Tang E, Zeng J, Shi X, Wang Y, Sun Y, Wu L.   +5 more
europepmc   +1 more source

Sulfonylurea [PDF]

, 2020
openaire   +1 more source

The sulfonylurea receptor

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1992
Ashcroft, S, Ashcroft, F
openaire   +2 more sources

Comparative effectiveness of combination therapy with SGLT‐2 inhibitors and GLP‐1 RAs compared with SGLT‐2 inhibitors in individuals with type 2 diabetes: A prevalent new‐user cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3273-3284, April 2026.
Abstract Aims To evaluate the effectiveness of combination therapy with sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) compared with continued SGLT‐2 inhibitor therapy in routine practice among individuals with type 2 diabetes.
Gregor A. Maier, Beata Hennig, Wolfgang Rathmann, Oliver Kuss   +3 more
wiley   +1 more source

A Five-Year Study on Treatment Changes in Hypoglycemia-Associated Medications: Towards Personalized Diabetes Management. [PDF]

J Pers Med
Asiri A, Cahyaningsih I, de Vos S, Bos JHJ, Schuiling-Veninga CCM, Hak E, Mubarik S, Denig P, Taxis K.   +8 more
europepmc   +1 more source